Table 1.
Spot | p-value | Fold-change | Protein ID | ACC. No. (Swissprot) | Gene | Sequence coverage (%) | No. peptides identified | Mr/pI |
---|---|---|---|---|---|---|---|---|
9* | 0.02 | 1.33 | Annexin A2 | P07355 | ANXA2 | 38.6 | 13 | 38/7.56 |
Ribose-phosphate pyrophosphokinase 1 | P60891 | PRPS1 | 15.1 | 4 | 35/6.56 | |||
Voltage-dependent anion-selective channel protein 2 | P45880 | VDAC2 | 17.70 | 5 | 32/7.5 | |||
Dual specificity mitogen-activated protein kinase kinase 6 | P52564 | MAP2K6 | 11.4 | 3 | 37/7.01 | |||
14* | 0.04 | 1.40 | Flotillin-1 | O75955 | FLOT1 | 62.3 | 23 | 47/7.08 |
Alpha-enolase | P06733 | ENO1 | 6.68 | 2 | 47/6.99 | |||
16* | 0.04 | -1.32 | Cdc42-interacting protein 4 | Q15462 | TRIP10 | 50.6 | 22 | 69/5.55 |
78 kDa glucose-regulated protein (GRP78) | P11021 | HSPA5 | 47.6 | 32 | 72/5.01 | |||
Collagen type IV alpha-3 binding protein | Q9Y5P4 | COL4A3BP | 20.7 | 9 | 71/5.29 | |||
NADH-ubiquinone oxireductase 75 kDa subunit, mitochondrial | P28331 | NDUFS1 | 13.2 | 8 | 79/5.42 | |||
Stress-70 protein, mitochondrial | P38646 | HSPA9 | 11.5 | 7 | 74/5.44 | |||
22* | 0.04 | -1.32 | cDNA FLJ5299 | A8K781 | cDNA FLJ5299 | 47.0 | 17 | 47/5.11 |
Keratin, type II cytoskeletal 8 | P05787 | KRT8 | 46.8 | 25 | 48/5.34 | |||
Thioredoxin domain-containing protein 5 | Q8NBS9 | TXNDC5 | 27.3 | 11 | 48/5.37 | |||
Actin, cytoplasmc 1 | P60709 | ACTB | 26.4 | 9 | 42/5.29 | |||
26S protease regulatory subunit 6B | P43686 | PSMC4 | 22.7 | 9 | 47/5.09 | |||
Uncharacterised protein KIAA0174 (ISTI homolog) | P53990 | KIAA0174 | 14.6 | 5 | 40/5.22 | |||
Eukaryotic initiation factor 4A-1 | P60842 | EIF4A1 | 16.0 | 5 | 46/5.32 | |||
Hsc70-interacting protein | P50502 | ST13 | 12.5 | 4 | 41/5.18 | |||
Heterogenous nuclear ribonucleoprotein F | P52597 | HNRNPF | 19.3 | 4 | 46/5.38 |
a Asterisk (*) denotes spots identified as containing a mixture of 2 or more proteins, or where protein isoforms cannot be distinguished based on peptides identified.
P-value and fold-change obtained based on normalised spot volume between control and IL11 treated group.